Core Viewpoint - The company, Gilead Sciences (1672.HK), announced a share buyback plan, which has led to a nearly 13% increase in its stock price, reaching HKD 11.25. The buyback is intended to enhance shareholder value and reflects the company's confidence in its long-term business prospects [1]. Financial Position - The company stated that its current financial condition is stable, allowing it to allocate up to HKD 300 million for the share buyback [1]. - The buyback authorization permits the company to repurchase up to 96.2846 million shares, which is equivalent to 10% of the total issued shares [1]. Strategic Intent - The board believes that the proposed share buyback will increase the value of the shares and improve returns for shareholders [1]. - The decision to repurchase shares demonstrates the company's confidence in its growth potential and long-term business outlook, which is expected to ultimately benefit the company and its shareholders [1]. - The company will ensure that the buyback does not significantly impact its operating capital [1].
港股异动丨歌礼制药拉升涨近13%，拟斥最多3亿元回购股份